I wanted to share some excerpts from a sort of "year in review" interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade. I found this article on a site called Mass High Tech.com earlier this month: Millennium reports myeloma drug advances, updates drug recalls By Lori Valigra, Mass High Tech correspondent Cambridge:
Here is Danny Parker's third installment from his weekly Diet and Multiple Myeloma series, just in time to help you plan for the new year: Diet and Multiple Myeloma (Part 3): Toasting the New Year Ironically, one of my best friends on the planet has multiple myeloma too and he knew he had it for
Medscape Today has released an excellent written and video review of multiple myeloma-related news from ASH. Dr. Paul Richardson, well known myeloma specialist with Dana-Farber in Boston, kicks things off by reviewing results from several exciting new, experimental drugs that his research group are studying. MLN9708, an oral proteasome inhibitor, and marizomib, a particularly potent
Last Wednesday, Californian Lori Puente stopped-in to visit our Nature Coast (Florida) Multiple Myeloma Support Group meeting and Christmas party. Her husband, Dave (the patient), was unable to attend because he was fighting a cold. Lori writes an excellent caregivers blog called Riding The Wave. She is a tireless advocate for the UAMS/Arkansas myeloma treatment
I hope everyone enjoyed their holiday weekend! I understand that some of you are concerned that I focus too much on all things multiple myeloma. Guilty as charged! But I do have fun now and then. Maybe I don't share that side with you often enough. So Surprise! I have hobbies. And believe it or
The Wall Street Journal's Peter Loftus reports that: "Johnson & Johnson doesn't expect to receive new supplies of its cancer drug Doxil from a troubled contract manufacturer's plant until late 2012, at the earliest. J&J will pursue other options to bring Doxil back to patients, including shifting production to another supplier, spokeswoman Lisa Vaga said
My sour stomach and cramps don't know it's Christmas. I'm up early again with dexamethasone induced stomach issues and cramps in my lower legs and hands. It isn't as bad as it was yesterday morning. Despite drinking nearly a liter of quinine filled tonic water, yesterday's cramping was the worst that I have ever experienced!
One of our readers, Ed from California, has had trouble posting comments. Sorry about that, Ed! For some reason, Ed's comments seem to get lost in the "world of moderation." I have yet to have one make it through to me for approval, even though he has tried several times. This "approval thing" isn't my
Yesterday I asked if this secondary cancer issue "is much to do about nothing, or something that concerns you enough to keep you up at night?" Based on the response, I have to conclude the answer is "NO!" I understand that this isn't a very pleasant topic to be discussing right before Christmas. We can
The risk of developing a secondary cancer following years of ongoing treatment was a red-hot issue one year ago. Why? A clinical study--presented at last year's ASH meetings in Orlando--showed multiple myeloma patients have an 8% risk of developing a secondary cancer if they use Revlimid maintenance following a stem cell transplant. The day following
I haven't written much about panobinostat , another new, combination drug lately. Here is a press release I saved from last week which was issued by the Dana-Farber Cancer Institute. I have highlighted several points that I think are important: Multiple Myeloma Treatment: Experimental drug combination encouraging in relapsed multiple myeloma San Diego- When the
Let's take a break from pharmaceutical related news from ASH, shall we? Here is the long awaited, second installment about diet and nutrition for multiple myeloma patients, contributed by guest columnist and high risk myeloma patient Danny Parker: Research on Diet and Myeloma So what can we learn by studying the available research on diet
I have heard from a number of you via email asking, "How am I feeling?" Thanks so much for caring! No doubt that I have gotten all wrapped-up in all things ASH this past week. Actually, I like it that way! Staying busy helps me to look past the day to day aches, pains and
New ASH data supports treating high risk smoldering myeloma patients. But is this really a good idea?
I don't post a lot of information about MGUS and smoldering multiple myeloma on this site. Sorry about that! There are two reasons for this. One is that I am so confident that the dozens of new, anti-myeloma therapies will be available by the time a smoldering myeloma patient needs them, I probably don't put
Data presented at the IMF’s Journalist Workshop takes me on an emotional roller-coaster ride (Part Three)
If your read Friday's post about my emotional evening at the IMF's International Jounalist event last week, you will probably recall how my roller-coaster "crashed down" after hearing about an unexpectedly short, 8 month overall survival (OS) benefit from using pomalidomid and dexamethasone after patients became refractory to Revlimid and Velcade. Today let’s work to
Yes, I've been busy! Here is a link to a post I wrote last Saturday for the IMF after spending some extra time in the poster exhibits: REFLECTIONS FROM ASH 2011 Pat Killingsworth is attending the 53rd American Society of Hematology Annual Meeting in San Diego, California with a group of other patients and caregivers...
I featured a number of links to important new therapy related news from ASH over the past few days at MyelomaNews.com. One of the links is to a Medscape Today article about vorinostat (trade name Zolinza), which includes comments from Dr. Noopur Raje, who I worked with a few weeks back in Cambridge. She is
Data presented at the IMF’s Journalist Workshop takes me on an emotional roller-coaster ride (Part Two)
I left off yesterday, talking about how a promising Revlimid maintenance clinical trial that was otherwise tarnished by a lack of improvement in overall survival (OS) among patients in the study. I forgot to mention that Dr. Richardson chimed-in, supporting Revlimid maintenance. “A similar study using thal/dex in the U.S. did show a measurable survival
Yesterday I set the stage for today’s report about research data which was featured at the International Myeloma Foundation’s Journalist Workshop Monday night. My original intention was to share a lot of specific data and facts--nothing but the facts. I plan to do just that--except for the “nothing but the facts” part. Because I think
Fresh off the plane from ASH in San Diego, last night I attended a special support group dinner meeting/seminar, hosted by Lourdes Arvelo with the Tampa area Leukemia & Lymphoma Society. True, after traveling five days, I would have prefered to stay home and enjoy a quiet evening with my wife. But the panel discussion